News Breaks |
|
|
| September 20, 2012 |
| 08:26 EDT |  | BMY, PFE | Bristol-Myers says unique profile positions Eliquis to be leader in class Says Eliquis opportunity assumes approval, which has not been granted yet. Comment from Bristol's President of U.S. Pharmaceuticals at UBS Health Care Conference. |
|
|
News For BMY;PFE From The Last 14 Days Check below for free stories on BMY;PFE the last two weeks. |
|
|
| May 23, 2013 |
| 06:02 EDT |  | BMY | Bristol-Myers implied volatility at upper end of index mean range
|
|
| 05:47 EDT |  | BMY | Stocks with implied volatility movement; SKS BMY Stocks with implied volatility movement; Saks (SKS), Bristol-Myers (BMY) according to IVolatility. |
|
| May 22, 2013 |
| 16:00 EDT |  | BMY | Options Update; May 22, 2013
Subscribe for More Information |
|
| 10:33 EDT |  | BMY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:16 EDT |  | BMY | Bristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information |
|
| 10:00 EDT |  | BMY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:59 EDT |  | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:06 EDT |  | PFE | Zoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information |
|
| 08:04 EDT |  | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 08:02 EDT |  | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
| |
| 06:05 EDT |  | BMY | Bristol-Myers upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 07:34 EDT |  | BMY | UBS to host a conference
Subscribe for More Information |
|
| 07:24 EDT |  | BMY | Global Health Care to host a conference
Subscribe for More Information |
|
| 07:16 EDT |  | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
|
| May 20, 2013 |
| 17:04 EDT |  | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information |
|
| 10:03 EDT |  | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 06:30 EDT |  | BMY | Leerink estimates Shire takeout value at least $110 per share Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT |  | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT |  | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT |  | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
| |
|
|
|
|